Figure 3.

Effect of TP53 exon 8 mutation on the clinical outcome of DLBCL patients. (A) CR rates in different groups based on TP53 status. CR status was evaluated by positron emission tomography–computed tomography scanning according to Lugano response criteria for non-Hodgkin’s lymphoma. Differences between groups of patients were assessed with the maximum likelihood chi-squared test. (B) PFS of different TP53 status groups. (C) PFS of IPI >2 group; patients with TP53 hotspot mutations, wild-type TP53, and non-hotspot TP53 mutations were compared. (D) Comparison of PFS between IPI 0–2 and IPI >2 groups with wild-type TP53 and non-hotspot TP53 mutations. Patients were followed up for 12 months until disease progression, relapse, or end of observation. PFS was defined as time to disease progression, relapse, or death, and was estimated with the Kaplan–Meier method and compared with the log-rank test.